RhumbLine Advisers
CANF

RhumbLine Advisers’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

RhumbLine Advisers’s Portfolio CANF Stock Details CANF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.8K Sell
17,433
-3,475
-17% -$10.9K ﹤0.01% 3674
2026
Q1 		$64.8K Buy
20,908
+6,814
+48% +$28.2K ﹤0.01% 3540
2025
Q4 		$56.4K Buy
14,094
+11,197
+387% +$87.7K ﹤0.01% 3613
2025
Q3 		$35.9K Buy
2,897
+18
+0.6% +$275 ﹤0.01% 3706
2025
Q2 		$60.5K Buy
2,879
+966
+50% +$22.2K ﹤0.01% 3642
2025
Q1 		$56.6K Buy
1,913
+569
+42% +$18.1K ﹤0.01% 3543
2024
Q4 		$43.7K Buy
1,344
+497
+59% +$20.2K ﹤0.01% 3676
2024
Q3 		$34.1K Buy
847
+77
+10% +$4.12K ﹤0.01% 3745
2024
Q2 		$39.7K Sell
770
-154
-17% -$7.29K ﹤0.01% 3742
2024
Q1 		$41K Hold
924
– – ﹤0.01% 3671
2023
Q4 		$40.7K Buy
924
+28
+3% +$1.2K ﹤0.01% 3667
2023
Q3 		$47.5K Buy
896
+41
+5% +$2.32K ﹤0.01% 3652
2023
Q2 		$52.5K Buy
+855
New +$40.2K ﹤0.01% 3671

Other funds holding CANF

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RhumbLine Advisers's CANF Position: Q2 2026 in Review

RhumbLine Advisers reduced its Can-Fite BioPharma American Depositary Shares (CANF) stake by 17% in Q2 2026, selling an estimated $10.9K and leaving 17,433 shares worth $51.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3674.

RhumbLine Advisers first reported a position in CANF in Q2 2023 and has held it in 13 quarters since. The position peaked at $64.8K in Q1 2026. 8 funds tracked by Wall St. Rank hold CANF as of Q2 2026.

  • RhumbLine Advisers held 17,433 shares of Can-Fite BioPharma American Depositary Shares worth $51.8K as of Q2 2026.
  • RhumbLine Advisers sold 3,475 Can-Fite BioPharma American Depositary Shares shares in Q2 2026, an estimated $10.9K.
  • Can-Fite BioPharma American Depositary Shares made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3674 holding.
  • RhumbLine Advisers first reported a position in Can-Fite BioPharma American Depositary Shares in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Can-Fite BioPharma American Depositary Shares position peaked at $64.8K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.